Search Results
Your search for ,foR matches 32393 pages
Showing 17601 - 176502018 William L. McGuire Award Nominations Now Being Accepted
Nominations are now being accepted for the William L. McGuire Award and Lectureship. The award is given annually at the San Antonio Breast Cancer Symposium in recognition of an investigator whose extraordinary and sustained achievements in translational and/or clinical research have made an impact ...
Huntsman Cancer Institute to Use National Cancer Institute Grant for Breast Cancer Trial Center
Huntsman Cancer Institute at the University of Utah has been awarded a $2.4 million 2-year grant from the National Cancer Institute to help continue its research in breast cancer. Alana Welm, PhD, and Bryan Welm, PhD, investigators at Huntsman Cancer Institute, along with Michael Lewis, PhD, a...
NCCN Summit Explores Survivorship Issues for Patients and Clinicians
When Yelak Biru was diagnosed with multiple myeloma in 1995, he and his physicians had one main posttreatment goal: to detect and treat any relapse early and to prolong survival as long as possible with the limited drugs available. Then, in the early 2000s, came newer treatments. Myeloma survival...
Clinical Hold on BPX-501 Trials in the United States Announced
On January 30, Bellicum Pharmaceuticals announced it has received notice from the U.S. Food and Drug Administration (FDA) that U.S. studies of BPX-501—an agent being studied to improve outcomes for patients undergoing stem cell transplant who lack a matched donor—have been placed on a clinical hold ...
EXPERT POINT OF VIEW: Ann H. Partridge, MD, MPH, FASCO
“The simple questions are whether ovarian function suppression adds clinical benefit in premenopausal women, and is ovarian function suppression better with an aromatase inhibitor or tamoxifen,” said formal discussant of these trials, Ann H. Partridge, MD, MPH, FASCO, Professor of Medicine at...
Ovarian Function Suppression During and After Chemotherapy Valid for Some Patients With Early Breast Cancer
Temporary ovarian suppression during chemotherapy as a means of preserving ovarian function and fertility in young women with early breast cancer is controversial. An eagerly awaited meta-analysis including individual patient data from five randomized controlled trials found that the use of...
EXPERT POINT OF VIEW: Matthew J. Ellis, MB, PhD
Matthew J. Ellis, MB, PhD, Director of the Lester and Sue Smith Breast Center at Baylor College of Medicine in Houston, commented on the POETIC trial for The ASCO Post. “This is a wonderful study that validates a point that our research team has also made over the years—that Ki67 is much more...
Perioperative Aromatase Inhibitors: No Effect on Recurrence, but Ki67 Level Important
Updated analysis from the United Kingdom’s POETIC trial found no evidence that perioperative aromatase inhibitor therapy slows or prevents time to recurrence of breast cancer. However, the study did show that tumor Ki67 levels after 2 weeks of perioperative aromatase inhibitor therapy are...
SABCS Highlights Focus on Predicting Residual Tumor Burden, Therapy-Related Arm Morbidity, Lifestyle and Cancer Risk
We have covered many of the important presentations from the 2017 San Antonio Breast Cancer Symposium in the pages of The ASCO Post and in our online Evening News. Here are summaries of additional noteworthy studies presented at the meeting. We hope you will find them of interest. Predicting...
Combined Medical and Psychological Approach May Help Couples Reclaim Intimacy After Prostate Cancer Treatment
“To what extent do treatments for prostate cancer impact sexual functioning? To a great extent,” Christian Nelson, PhD, Chief, Psychiatry Service, Memorial Sloan Kettering Cancer Center, New York, told participants at the 11th Annual Oncofertility Consortium Conference in Chicago.1 Most men with...
Stand Up To Cancer Awards $11M to Study Immune Response to Cancer
Stand Up To Cancer (SU2C) has announced a “Convergence 2.0” research initiative that awards $11 million to 7 multidisciplinary research teams to investigate immune system response to cancer. The multi-institutional teams were announced at SU2C’s Scientific Summit. Each team comprises experts in...
James P. Allison, PhD, Granted BBVA Foundation Award for Groundbreaking Work in Immunotherapy
The BBVA Foundation awarded its Frontiers of Knowledge Award in the Biomedicine category to American immunologist James P. Allison, PhD, whose innovative research has almost single-handedly transformed cancer treatment. His seminal research in immunotherapy has paved the way for the development of ...
ASCO Endorses CAP/IASLC/AMP Guideline Update on Molecular Testing for Targeted Tyrosine Kinase Inhibitor Treatment in Lung Cancer
As reported in the Journal of Clinical Oncology by Gregory P. Kalemkerian, MD, and colleagues, ASCO has endorsed the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) updated guideline on molecular...
First-Line Lenvatinib vs Sorafenib in Unresectable Hepatocellular Carcinoma
In a phase III noninferiority trial reported in The Lancet, Kudo et al found that first-line lenvatinib was noninferior to sorafenib in overall survival of patients with unresectable hepatocellular carcinoma. Study Details In the open-label trial, 954 patients from 154 sites in 20 countries in...
New International Practice Guidelines for Using CYP2D6 Genotype to Guide Antiestrogen Treatment in Breast Cancer
An international group of clinicians and scientists representing the Clinical Pharmacogenetics Implementation Consortium (CPIC) published the first-ever clinical practice guidelines for using CYP2D6 genotype to guide tamoxifen therapy. Their research was published by Goetz et al in Clinical...
New ACCC Report Focuses on Immuno-Oncology, Cancer Care Delivery
As innovations in immunotherapies multiply, cancer programs and practices must overcome care coordination and communication challenges across the nation’s health-care system to integrate these advances into effective patient care. A new report from the Association of Community Cancer Centers...
EXPERT POINT OF VIEW: Brian M. Wolpin, MD, MPH
Invited discussant Brian M. Wolpin, MD, MPH, of Dana-Farber Cancer Institute in Boston, said the results of the LAPACT trial will be useful as an aid to patient counseling as well as in designing and interpreting future studies. However, he added, they are not “practice-changing,” as nanoparticle...
LAPACT Trial Confirms Efficacy of Nab-Paclitaxel Plus Gemcitabine as Induction Therapy in Pancreatic Cancer
Patients newly diagnosed with locally advanced pancreatic cancer who received induction therapy with nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) and gemcitabine achieved a time to treatment failure and median progression-free survival that exceeded the protocol-specified target by more...
EXPERT POINT OF VIEW: Douglas Corley, MD, PhD and Nancy Baxter, MD
In a discussion of the study, Douglas Corley, MD, PhD, of the Division of Research at Kaiser Permanente, San Francisco Medical Center, California, said it remains unclear whether blood tests can improve the early detection of cancer, though such an approach would be welcomed. “We are getting closer ...
Use of Circulating Tumor Cells to Detect Colorectal Cancer and Adenomas
Circulating tumor cells (CTCs) in the blood had an accuracy of up to 88% in detecting colorectal cancer and 84% in identifying adenomas, in a study from Taiwan presented at the 2018 Gastrointestinal Cancers Symposium by Wen-Sy Tsai, MD, of Linkou Chang Gung Memorial Hospital in Taipei.1 “The study ...
EXPERT POINT OF VIEW: Jordi Bruix, MD, PhD and Flavio G. Rocha, MD
Discussant Jordi Bruix, MD, PhD, Head of the Barcelona Clinic Liver Cancer Group at the University of Barcelona in Spain, said the results of the CELESTIAL trial show that cabozantinib (Cabometyx) provides a clinically meaningful survival benefit to patients with advanced hepatocellular carcinoma ...
Cabozantinib Improves Survival in Advanced Hepatocellular Carcinoma
Patients with previously treated advanced hepatocellular carcinoma derived a survival benefit from cabozantinib (Cabometyx), in the phase III CELESTIAL trial.1 “Cabozantinib represents a new treatment option for patients with advanced hepatocellular carcinoma after prior systemic anticancer...
Releasing Follicular Lymphoma From the Curse of Frankenstein
In the December 10, 2017, issue of The ASCO Post, I authored an article in which I raised the possibility of curing follicular lymphoma without the dreaded chemotherapy. Clearly, no good deed goes unpunished: My good friend and The ASCO Post’s editor Jim Armitage, MD, challenged me to defend that...
Laryngeal Preservation: All Patients Need a Voice
Following the publication of two landmark studies in the United States,1,2 laryngeal preservation with combined chemoradiotherapy has become standard practice as opposed to laryngectomy for patients with locally advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study...
EXPERT POINT OF VIEW: Ravindra Uppaluri, MD, PhD
“This is a large, well-done study,” said Ravindra Uppaluri, MD, PhD, Chief of the Division of Otolaryngology in the Department of Surgery at the Brigham and Women’s Hospital and Director of Head and Neck Surgical Oncology at Dana-Farber Cancer Institute, who underscored the small number of...
Combination Radiotherapy and Immunotherapy Appears Safe and Clinically Active in Advanced Solid Tumors
Results from the first and largest prospective trial to determine the safety of multisite ablative stereotactic body radiotherapy (SBRT) in combination with anti–programmed cell death protein 1 (anti–PD-1) immunotherapy pembrolizumab (Keytruda) suggest the combination regimen may improve outcomes...
Combination Immunotherapy in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
As reported in the Journal of Clinical Oncology by Overman et al, findings in the nivolumab (Opdivo) plus ipilimumab (Yervoy) cohort of the CheckMate-142 study indicate a high response rate and durable responses with the combination in previously treated patients with DNA mismatch...
Long-Term Survival Outcomes With Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Analysis of long-term survival outcomes in the phase III CHAARTED trial showed a survival advantage with the addition of docetaxel to androgen-deprivation therapy (ADT) in patients with hormone-sensitive metastatic prostate cancer, although no advantage was observed among patients with low-volume...
2018 GU CANCERS SYMPOSIUM: Tivozanib in Combination With Nivolumab in Metastatic RCC
Preliminary results from the phase II portion of the TiNivo study, a phase Ib/II multicenter trial of oral tivozanib in combination with intravenous (IV) nivolumab (Opdivo) for the treatment of metastatic renal cell carcinoma (RCC) were presented by Escudier et al at the 2018 Genitourinary Cancers...
ASCO Examines the Current Oncology Clinical Pathways Landscape
ASCO has released its review of leading oncology pathway vendors in the United States. “Oncology Clinical Pathways: Charting the Landscape of Pathway Providers,” published in the Journal of Oncology Practice (JOP), examines the clinical pathways offered by six commercial vendors using...
ASCO and NCCN Provide Guidelines for Managing Immunotherapy Side Effects
Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body's immune system to attack cancer, these treatments can send even the most hard-to-treat cancers into...
FDA Approves Apalutamide for Nonmetastatic, Castration-Resistant Prostate Cancer
The U.S. Food and Drug Administration (FDA) today approved apalutamide (Erleada) for the treatment of patients with prostate cancer that has not spread, but that continues to grow despite treatment with hormone therapy. This is the first FDA-approved treatment for nonmetastatic,...
Neoadjuvant Trastuzumab Biosimilar vs Trastuzumab in HER2-Positive Early Breast Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Pivot et al found equivalence of the trastuzumab biosimilar SB3 and the reference trastuzumab (Herceptin) in producing breast pathologic complete response in the neoadjuvant treatment of patients with HER2-positive early breast...
ALK Variant, Resistance, and Clinical Outcomes in ALK-Positive NSCLC
In a study reported in the Journal of Clinical Oncology, Lin et al found that specific ALK variants may be associated with the development of resistance mutations to ALK tyrosine kinase inhibitors (TKIs) in ALK-positive non–small cell lung cancer (NSCLC). Study Details The study involved...
METEOR Trial Follow-up: Quality of Life in Metastatic RCC
In a study reported in the Journal of Clinical Oncology, Cella et al found little difference in quality-of-life (QOL) outcomes between the cabozantinib (Cabometyx) and everolimus (Afinitor) groups in the phase III METEOR trial. The study investigated these treatments in patients with metastatic...
FDA Grants Priority Review to Lorlatinib in ALK-Positive NSCLC
On February 12, the U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to Pfizer’s new drug application for lorlatinib. The Prescription Drug User Fee Act goal date for a decision by the FDA is in August 2018. Lorlatinib is an investigational, anaplastic lymphoma...
FDA Grants Premarket Approval to New HPV Assay
On February 14, Becton, Dickinson and Company (BD) announced it had received premarket approval from the U.S. Food and Drug Administration (FDA) for the BD Onclarity human papillomavirus (HPV) assay. The test detects 14 types of high-risk HPV from specimens collected for cervical cancer screening...
2018 SURVIVORSHIP: Many Young Adult Cancer Survivors Forgo Follow-up Care After Cancer Treatment Ends
Despite survivorship guidelines from ASCO and other organizations regarding follow-up care after cancer treatment ends, follow-up care is generally lacking for adolescent and young adult (AYA) cancer survivors. Since AYA cancer survivors are at an increased risk for late effects from their cancer...
2018 SURVIVORSHIP: Therapeutic Sexual Aids Frequently Not Available for Cancer Survivors Who Need Them
Cancer care guidelines recommend that cancer survivors who experience sexual dysfunction after cancer treatment use therapeutic aids to help improve their sexual health. However, a new study of 25 leading cancer centers found that 87% of the centers reported having no sexual aids available on site...
2018 SURVIVORSHIP: Exercise Speeds Improvement in Arm Mobility After Surgery for Breast Cancer
New findings from a clinical trial of women with breast cancer suggest that guided exercise with a physical therapist after lymph node dissection helps women regain their range of arm motion more quickly. These findings will be presented by Paskett et al at the upcoming 2018 Cancer Survivorship...
2018 SURVIVORSHIP: Exercising During Chemotherapy for Breast or Colon Cancer Has Long-Term Benefits
A follow-up study to a randomized clinical trial reveals that exercising during adjuvant chemotherapy helps people engage in more physical activity years later. Four years later, people with breast or colon cancer who had participated in an 18-week exercise program while receiving chemotherapy...
2018 SURVIVORSHIP: Web-Based Interventions Help Adolescents Stay Physically Active After Cancer Treatment
Survivors of childhood cancer are at increased risk for obesity and metabolic syndrome, which can lead to other serious health conditions, including heart disease, stroke, and diabetes. However, engaging in regular physical activity may help remediate these health issues in young survivors. A...
Gregory R. Pond, PhD, on Urothelial Cancer: Advance in Prognosis
Gregory R. Pond, PhD, of McMaster University, discusses a new six-factor prognostic model for patients with advanced urothelial carcinoma receiving post platinum atezolizumab (Abstract 413).
Paul L. Nguyen, MD, on Prostate Cancer: Abstract Roundup
Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he chaired on prostate cancer, which included discussion of daily vs weekly image-guided radiotherapy; a biomarker to predict biochemical failure and metastasis; a comparison of abiraterone or enzalutamide activity; and...
Daniel J. George, MD, on RCC: Results From the Alliance A031203 CABOSUN Trial
Daniel J. George, MD, of Duke University Medical Center, discusses study findings on cabozantinib vs sunitinib for previously untreated patients with advanced renal cell carcinoma of intermediate or poor risk, in a subgroup analysis of progression-free survival and objective response rates...
John J. Coen, MD, on Bladder Cancer: Results From the NRG/RTOG 0712 Trial
John J. Coen, MD, of 21st Century Oncology, discusses phase II study findings on selective bladder preservation with twice-daily radiation plus fluorouracil/cisplatin or daily radiation plus gemcitabine for patients with muscle-invasive bladder cancer (Abstract 408).
Selective Inhibition of Nuclear Export in Heavily Pretreated Relapsed or Refractory Multiple Myeloma
In a phase II trial reported in the Journal of Clinical Oncology, Vogl et al found that the investigational oral selective exportin 1 (XPO1) inhibitor selinexor combined with dexamethasone produced responses in patients with heavily pretreated relapsed or refractory multiple myeloma. ...
Synchronous Distant and Locoregional Recurrence in Stage II and III Breast Cancer
In a study of National Cancer Database data reported in the Journal of Clinical Oncology, Neuman et al found that synchronous distant recurrence was identified in 27% of women with stage II or III breast cancer experiencing locoregional recurrence. Study Details The study—an American...
2018 GU CANCERS SYMPOSIUM: Antiandrogenic Therapy in Nonmetastatic Castration-Resistant Prostate Cancer
Results from the phase III PROSPER trial in patients with nonmetastatic castration-resistant prostate cancer were presented by Hussain et al at the 2018 Genitourinary Cancers Symposium (Abstract 3). The results show that the use of enzalutamide (Xtandi) plus androgen-deprivation therapy (ADT)...
2018 GU CANCERS SYMPOSIUM: Early-Phase Trial of Glutaminase Inhibitor CB-839 in Combination With Cabozantinib or Everolimus in Renal Cell Carcinoma
Data on CB-839, a first-in-class glutaminase inhibitor, will be presented by Tannir et al at the 2018 Genitourinary Cancers Symposium in San Francisco (Abstract 603). The data are from the CX-839-001 study, which includes cohorts evaluating the safety, efficacy and recommended phase II dose of ...
